Clinical Trials Logo

Clinical Trial Summary

Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade [1]. This threat underscores the need to maximize clinical utility of existing antibiotics, through more rational prescription, e.g. optimizing duration of treatment.

Staphylococcus aureus bloodstream infection (SAB) is a common disease with about 200,000 cases occurring annually in Europe [2]. A course of at least 14 days of intravenous antimicrobials is considered standard therapy [3-5] in "uncomplicated" SAB. This relatively long course serves to prevent SAB-related complications (such as endocarditis and vertebral osteomyelitis) that may result from hematogenous dissemination to distant sites. However, there is insufficient evidence that a full course of intravenous antibiotic therapy is always required in patients with a low risk of SAB-related complications.

In a multicenter, open-label, randomized controlled trial we aim to demonstrate that an early switch from intravenous to oral antimicrobial therapy is non-inferior to a conventional 14-days course of intravenous therapy regarding efficacy and safety. An early switch from intravenous to oral therapy would provide several benefits such as earlier discharge, fewer adverse reactions associated with intravenous therapy, increased quality of life, and cost savings.


Clinical Trial Description

1. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health Organization, 2001.

2. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010;23(4):346-58.

3. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57(4):589-608.

4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55.

5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01792804
Study type Interventional
Source Heinrich-Heine University, Duesseldorf
Contact
Status Completed
Phase Phase 3
Start date December 2013
Completion date March 26, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04210505 - Nasal Decolonization of Dialysis Patients Noses Phase 4
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02804711 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT02282605 - Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Enrolling by invitation NCT06317688 - Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Phase 1
Withdrawn NCT02741869 - Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients N/A
Completed NCT03966040 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Recruiting NCT05117398 - Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus Phase 3
Completed NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 0
Active, not recruiting NCT01879761 - Immune Resolution After Staphylococcus Aureus Bacteremia
Completed NCT01375621 - Livestock Contact and MRSA in Rural Areas
Recruiting NCT00532324 - Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns N/A
Completed NCT04503252 - Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4
Enrolling by invitation NCT04897971 - Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
Completed NCT00572910 - A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) Phase 2
Recruiting NCT04712123 - Recurrent S. Aureus Infections in Osteoarticular Infections
Not yet recruiting NCT06210594 - Staph Intervention for Effective Local Defense Phase 4